Tesaro, Inc. Describes Initial Phase 1 Clinical Data for TSR-011 Presented at the European Cancer Congress 2013

Published: Sep 30, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AMSTERDAM, Netherlands, Sept. 29, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, presented initial data from a Phase 1 trial of TSR-011 today at the European Cancer Congress in Amsterdam. TSR-011 is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases (TRK). Preliminary clinical activity has been observed in this study in one papillary thyroid carcinoma patient and one pancreatic cancer patient without ALK expression, and in three patients with ALK-positive non-small cell lung cancer (NCSLC) who progressed following prior treatment with crizotinib.

Help employers find you! Check out all the jobs and post your resume.

Back to news